Crohn's Disease Clinical Trial
NCT04173273
| Phase 3
| Interventional
This study is looking to recruit 1115 Participants
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy,
safety, and tolerability of oral etrasimod as therapy in adult participants with moderately
to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the
current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall
duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment
Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension
Periods), and the 4-Week Follow-Up Period for safety assessment.
Details for the study
Brief Title
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease
Official Title
A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn's Disease
Brief Summary
This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy,
<br /> safety, and tolerability of oral etrasimod as therapy in adult participants with moderately
<br /> to severely active Crohn's disease (CD) who are refractory or intolerant to at least 1 of the
<br /> current therapies for CD (ie, corticosteroids, immunosuppressants, or biologics). The overall
<br /> duration of this study is up to 282 weeks, inclusive of the Screening Period, Treatment
<br /> Period of up to 274 weeks (Induction, Extension or Maintenance, and Long-term Extension
<br /> Periods), and the 4-Week Follow-Up Period for safety assessment.
Detailed Description
This study includes 5 substudies:
Substudy A - Phase 2: A Phase 2, randomized, double-blind, substudy to assess the safety,
tolerability, and efficacy of oral etrasimod therapy in participants with moderate to severe
CD that supports the selection of an induction and maintenance dose(s) for Phase 3.
Substudy 1 - Phase 2: A Phase 2b randomized, double-blind, placebo-controlled, dose-ranging
induction substudy to evaluate etrasimod as induction therapy and select an induction and
maintenance dose(s) for continued evaluation in Phase 3.
Substudy 2 - Induction: A Phase 3 randomized, double-blind, placebo-controlled substudy to
evaluate etrasimod as induction therapy.
Substudy 3 - Maintenance: A Phase 3 randomized, double-blind, placebo-controlled substudy to
evaluate etrasimod as maintenance therapy. Participants from Substudy 1 and Substudy 2 will
be enrolled in Substudy 3.
Substudy 4 - Long-Term Extension: A long-term extension substudy for participants who
complete at least 52 weeks of treatment. Participants from Substudy 3 and Substudy A are
planned to be enrolled in Substudy 4.
Treatments and/or Procedures
Placebo
Etrasimod matching placebo tablet taken by mouth, once daily.
Etrasimod
Dose B taken by mouth, once daily.
Etrasimod
Dose A taken by mouth, once daily.
Outcome Measures
Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.
Secondary
Number and Severity of Adverse Events
Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.
Study Criteria
Eligibility criteria applicable to all substudies:
Inclusion Criteria:
- Men or women 18 to 80 years of age,
- Ability to provide written informed consent or assent and to be compliant with the
schedule of protocol assessments
- Diagnosed with Crohn's disease (CD) ≥ 3 months
- Have moderately to severely active CD at Screening
- Demonstrated inadequate response (ie, primary non-response), loss of response to, or
intolerance to ≥ 1 of the following therapies for the treatment of CD:
1. Oral corticosteroids (eg, prednisone or its equivalent, budesonide)
2. Immunosuppressants (eg, azathioprine [AZA], 6 mercaptopurine [6-MP], or
methotrexate [MTX])
3. Tumor necrosis factor alpha (TNFα) antagonists (eg, infliximab, adalimumab,
certolizumab pegol, or biosimilars)
4. Integrin receptor antagonist (eg, vedolizumab)
5. Interleukin -12/-23 antagonist (eg, ustekinumab)
- Females of childbearing potential must be nonpregnant
- Females of childbearing potential and males must use contraception
Exclusion Criteria:
- History of inadequate response (ie, primary non-response) to agents from ≥ 2 classes
of biologics marketed for the treatment of CD (ie, TNFα antagonists, interleukin 12/
23 antagonist, and integrin receptor antagonist).
- Have ulcerative colitis, indeterminate colitis, microscopic colitis, ischemic colitis,
radiation colitis, diverticular disease associated colitis, toxic megacolon, or active
infectious colitis or test positive for Clostridioides difficile toxin at Screening.
- Have functional or post-operative short-bowel syndrome or any associated complications
that may require surgery or interfere with efficacy assessments
- Had surgical treatment for intra abdominal abscesses ≤ 8 weeks prior to randomization
or surgical treatment for perianal abscesses ≤ 4 weeks prior to randomization.
- Had intestinal resection ≤ 24 weeks prior to randomization or other intra abdominal
surgeries ≤ 12 weeks prior to randomization.
- Have an ileostomy or a colostomy.
Inclusion Criteria for Substudy 3:
- Participants who entered the Extended Induction Period of Substudy 1 and Substudy 2 must
have completed the Extended Induction -Week 6 Visit
Inclusion Criteria for Substudy 4:
- Participant must have completed the Week 52 Visit of Substudy 3 or the Week 66 Visit of
Substudy A
